Manager - Procurement
- Hyderabad, IN
2022-12-07 08:46:42 UTC
PopVax is an Indian biotechnology company based in Hyderabad, with a primarily remote US subsidiary nominally based in New York. We are funded via research agreements with the Gates Foundation and Vitalik Buterin’s biosecurity company Balvi. For the past year, we have been building a novel second-generation mRNA platform for low-cost broadly-protective vaccines via computationally-driven antigen design, starting with an open-source booster vaccine candidate that is intended to protect against the entire sarbecovirus species and, if things go well, the betacoronavirus genus, including current and future strains of SARS-CoV-2, the virus which causes COVID-19.
We’re looking for an experienced procurement manager with at least 5 years of experience in procuring materials for pharmaceutical formulations, preferably vaccines.
5+ years of experience in sourcing a wide range of pharmaceutical materials, including biological materials like enzymes. Also, materials for R&D as well as equipments and instruments, both for manufacturing and R&D
Experience dealing with small and large local and multinational vendors with proven negotiation skills and commercial acumen
Well versed with customs clearance procedures for imports
Familiarity with logistics of materials supply, especially international freight forwarding of temperature sensitive materials
Knowledge of ERP systems like SAP for purchase activities
Experience of vendor development including participation in vendor audits
Background knowledge of relevant national and international guidelines around vendor development, audits and documentation, as laid out by CDSCO/DCGI, WHO, and US FDA
Good oral and written communication skills with the ability to work with multifunctional teams
We offer very competitive compensation, comprehensive health insurance covering immediate family (including pre-existing conditions), and, most importantly, a collaborative work environment focused on solving the cutting-edge multidisciplinary challenges of our novel mRNA platform.